Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Pharmacokinetics of SN2310, an injectable emulsion that incorporates a new derivative of SN-38 in patients with advanced solid tumors.

Marier JF, Pheng L, Trinh MM, Burris HA 3rd, Jones S, Anderson K, Warner S, Porubek D.

J Pharm Sci. 2011 Oct;100(10):4536-45. doi: 10.1002/jps.22645. Epub 2011 May 31.

PMID:
21630281
2.

Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction.

Schaaf LJ, Hammond LA, Tipping SJ, Goldberg RM, Goel R, Kuhn JG, Miller LL, Compton LD, Cisar LA, Elfring GL, Gruia G, McGovren JP, Pirotta N, Yin D, Sharma A, Duncan BA, Rothenberg ML.

Clin Cancer Res. 2006 Jun 15;12(12):3782-91.

3.

Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer.

Boige V, Raymond E, Faivre S, Gatineau M, Meely K, Mekhaldi S, Pautier P, Ducreux M, Rixe O, Armand JP.

J Clin Oncol. 2000 Dec 1;18(23):3986-92.

PMID:
11099328
4.

Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin.

de Jonge MJ, Verweij J, de Bruijn P, Brouwer E, Mathijssen RH, van Alphen RJ, de Boer-Dennert MM, Vernillet L, Jacques C, Sparreboom A.

J Clin Oncol. 2000 Jan;18(1):195-203.

PMID:
10623710
5.

A phase I, dose-finding study of irinotecan (CPT-11) short i.v. infusion combined with fixed dose of 5-fluorouracil (5-FU) protracted i.v. infusion in adult patients with advanced solid tumours.

Sastre J, Paz-Ares L, Carcas A, Alfonso R, Grávalos C, Frías J, Guerra P, Pronk L, Cortés-Funes H, Díaz-Rubio E.

Cancer Chemother Pharmacol. 2005 May;55(5):453-60. Epub 2004 Oct 26.

PMID:
15818508
6.

Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors.

Catimel G, Chabot GG, Guastalla JP, Dumortier A, Cote C, Engel C, Gouyette A, Mathieu-Boué A, Mahjoubi M, Clavel M.

Ann Oncol. 1995 Feb;6(2):133-40.

PMID:
7786821
7.
8.

A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors.

Pitot HC, Adjei AA, Reid JM, Sloan JA, Atherton PJ, Rubin J, Alberts SR, Duncan BA, Denis L, Schaaf LJ, Yin D, Sharma A, McGovren P, Miller LL, Erlichman C.

Cancer Chemother Pharmacol. 2006 Aug;58(2):165-72. Epub 2005 Nov 19.

PMID:
16328416
9.

Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients.

Chang TC, Shiah HS, Yang CH, Yeh KH, Cheng AL, Shen BN, Wang YW, Yeh CG, Chiang NJ, Chang JY, Chen LT.

Cancer Chemother Pharmacol. 2015 Mar;75(3):579-86. doi: 10.1007/s00280-014-2671-x. Epub 2015 Jan 11.

10.

Clinical pharmacokinetics of irinotecan.

Chabot GG.

Clin Pharmacokinet. 1997 Oct;33(4):245-59. Review.

PMID:
9342501
11.

Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors.

Herben VM, Schellens JH, Swart M, Gruia G, Vernillet L, Beijnen JH, ten Bokkel Huinink WW.

J Clin Oncol. 1999 Jun;17(6):1897-905.

PMID:
10561231
12.

Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials.

Chabot GG, Abigerges D, Catimel G, Culine S, de Forni M, Extra JM, Mahjoubi M, Hérait P, Armand JP, Bugat R, et al.

Ann Oncol. 1995 Feb;6(2):141-51.

PMID:
7786822
13.

Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients.

Takimoto CH, Morrison G, Harold N, Quinn M, Monahan BP, Band RA, Cottrell J, Guemei A, Llorens V, Hehman H, Ismail AS, Flemming D, Gosky DM, Hirota H, Berger SJ, Berger NA, Chen AP, Shapiro JD, Arbuck SG, Wright J, Hamilton JM, Allegra CJ, Grem JL.

J Clin Oncol. 2000 Feb;18(3):659-67.

PMID:
10653882
14.

Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan.

Ma MK, Zamboni WC, Radomski KM, Furman WL, Santana VM, Houghton PJ, Hanna SK, Smith AK, Stewart CF.

Clin Cancer Res. 2000 Mar;6(3):813-9.

15.

Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.

Abigerges D, Chabot GG, Armand JP, Hérait P, Gouyette A, Gandia D.

J Clin Oncol. 1995 Jan;13(1):210-21.

PMID:
7799022
16.

Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38.

Mathijssen RH, Verweij J, Loos WJ, de Bruijn P, Nooter K, Sparreboom A.

Br J Cancer. 2002 Jul 15;87(2):144-50.

17.

Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide.

Klein CE, Gupta E, Reid JM, Atherton PJ, Sloan JA, Pitot HC, Ratain MJ, Kastrissios H.

Clin Pharmacol Ther. 2002 Dec;72(6):638-47.

PMID:
12496745
18.

Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks.

Rothenberg ML, Kuhn JG, Schaaf LJ, Rodriguez GI, Eckhardt SG, Villalona-Calero MA, Rinaldi DA, Hammond LA, Hodges S, Sharma A, Elfring GL, Petit RG, Locker PK, Miller LL, von Hoff DD.

Ann Oncol. 2001 Nov;12(11):1631-41.

19.
20.
Items per page

Supplemental Content

Write to the Help Desk